(Q39359690)

English

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

scientific article published on 19 September 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

11 September 2017

phase III clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

11 September 2017

object named as

David J Kerr

15

0 references

object named as

Enric Domingo

14

0 references

13

object named as

Ian Tomlinson

1 reference

Europe PubMed Central

11 September 2017

6

object named as

Peter Hewett

1 reference

Europe PubMed Central

11 September 2017

Elaine C Johnstone

4

object named as

Elaine Johnstone

1 reference

Europe PubMed Central

11 September 2017

author name string

Rachel S Kerr

1

1 reference

Europe PubMed Central

11 September 2017

Sharon Love

2

1 reference

Europe PubMed Central

11 September 2017

Beverly Falcon

5

1 reference

Europe PubMed Central

11 September 2017

Andrew Weaver

7

1 reference

Europe PubMed Central

11 September 2017

David Church

8

1 reference

Europe PubMed Central

11 September 2017

Claire Scudder

9

1 reference

Europe PubMed Central

11 September 2017

Sarah Pearson

10

1 reference

Europe PubMed Central

11 September 2017

Patrick Julier

11

1 reference

Europe PubMed Central

11 September 2017

Francesco Pezzella

12

1 reference

Europe PubMed Central

11 September 2017

publication date

19 September 2016

1 reference

Europe PubMed Central

11 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

11 September 2017

17

1 reference

Europe PubMed Central

11 September 2017

1543-1557

1 reference

Europe PubMed Central

11 September 2017

11

1 reference

Europe PubMed Central

11 September 2017

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-content multiplexed tissue imaging and quantification for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of new morphometric parameters of neoangiogenesis in human colorectal cancer using confocal laser endomicroscopy (CLE) and targeted panendothelial markers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30172-3

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39359690&oldid=1836074686"